» Articles » PMID: 21416464

Vstm3 is a Member of the CD28 Family and an Important Modulator of T-cell Function

Abstract

Members of the CD28 family play important roles in regulating T-cell functions and share a common gene structure profile. We have identified VSTM3 as a protein whose gene structure matches that of the other CD28 family members. This protein (also known as TIGIT and WUCAM) has been previously shown to affect immune responses and is expressed on NK cells, activated and memory T cells, and Tregs. The nectin-family proteins CD155 and CD112 serve as counter-structures for VSTM3, and CD155 and CD112 also bind to the activating receptor CD226 on T cells and NK cells. Hence, this group of interacting proteins forms a network of molecules similar to the well-characterized CD28-CTLA-4-CD80-CD86 network. In the same way that soluble CTLA-4 can be used to block T-cell responses, we show that soluble Vstm3 attenuates T-cell responses in vitro and in vivo. Moreover, animals deficient in Vstm3 are more sensitive to autoimmune challenges indicating that this new member of the CD28 family is an important regulator of T-cell responses.

Citing Articles

Immune Checkpoints Are New Therapeutic Targets in Regulating Cardio-, and Cerebro-Vascular Diseases and CD4Foxp3 Regulatory T Cell Immunosuppression.

Shao Y, Yang W, Nanayakkara G, Saaoud F, Ben Issa M, Xu K Int J Drug Discov Pharm. 2025; 3(4).

PMID: 39926714 PMC: 11804271. DOI: 10.53941/ijddp.2024.100022.


Turning Cancer Immunotherapy to the Emerging Immune Checkpoint TIGIT: Will This Break Through the Limitations of the Legacy Approach?.

Cui H, Elkord E Vaccines (Basel). 2025; 12(12.

PMID: 39771968 PMC: 11679306. DOI: 10.3390/vaccines12121306.


Nanobodies as innovative immune checkpoint modulators: advancing cancer immunotherapy.

Hosseininejad-Chafi M, Eftekhari Z, Oghalaie A, Behdani M, Sotoudeh N, Kazemi-Lomedasht F Med Oncol. 2024; 42(1):36.

PMID: 39719469 DOI: 10.1007/s12032-024-02588-y.


Revisiting T-cell adhesion molecules as potential targets for cancer immunotherapy: CD226 and CD2.

Jo Y, Sim H, Yun B, Park Y, Jin H Exp Mol Med. 2024; 56(10):2113-2126.

PMID: 39349829 PMC: 11541569. DOI: 10.1038/s12276-024-01317-9.


Surface Immune Checkpoints as Potential Biomarkers in Physiological Pregnancy and Recurrent Pregnancy Loss.

Zych M, Kniotek M, Roszczyk A, Dabrowski F, Jedra R, Zagozdzon R Int J Mol Sci. 2024; 25(17).

PMID: 39273326 PMC: 11395075. DOI: 10.3390/ijms25179378.


References
1.
Bottino C, Castriconi R, Pende D, Rivera P, Nanni M, Carnemolla B . Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med. 2003; 198(4):557-67. PMC: 2194180. DOI: 10.1084/jem.20030788. View

2.
Abbas A, Lohr J, Knoechel B, Nagabhushanam V . T cell tolerance and autoimmunity. Autoimmun Rev. 2004; 3(7-8):471-5. DOI: 10.1016/j.autrev.2004.07.004. View

3.
Tahara-Hanaoka S, Shibuya K, Kai H, Miyamoto A, Morikawa Y, Ohkochi N . Tumor rejection by the poliovirus receptor family ligands of the DNAM-1 (CD226) receptor. Blood. 2005; 107(4):1491-6. DOI: 10.1182/blood-2005-04-1684. View

4.
Reymond N, Imbert A, Devilard E, Fabre S, Chabannon C, Xerri L . DNAM-1 and PVR regulate monocyte migration through endothelial junctions. J Exp Med. 2004; 199(10):1331-41. PMC: 2211807. DOI: 10.1084/jem.20032206. View

5.
Peggs K, Quezada S, Korman A, Allison J . Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol. 2006; 18(2):206-13. DOI: 10.1016/j.coi.2006.01.011. View